AzTrials
AzTrials

Evaluate the Prototype Digital Vaccine PlatformNCT06843876

The Evaluation of The Prototype Digital Vaccine Platform "TM-VAX" Among User in The Hospital for Tropical Diseases

A study testing digital vaccine platform "TM VAX" application in people with Evaluate the Prototype Digital Vaccine Platform, run by Mahidol University at 1 site in Thailand.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

RATIONALE: Digital technology plays a key role in modern healthcare, impacting diagnosis, treatment, and health information management. Vaccination is a critical tool for disease prevention, reducing healthcare costs, and enhancing quality of life. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
digital vaccine platform "TM VAX" application
Type of treatment
Vaccines
Could I receive a placebo?
No, everyone receives an active treatment
How many people
202 participants
Where
1 siteThailand
Study dates
1 May 2025to 30 Oct 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthcare Provider:
  • Aged 18 years or older
  • Thai nationality
  • Currently working at the Hospital for Tropical Diseases, regardless of work duration
  • Have basic skills in using computers, mobile phones, and the internet
  • Willing to participate in the study
Show all 11Show fewer
  • Patients:
  • Aged 18 years or older
  • Thai nationality
  • Have basic skills in using computers, mobile phones and the internet
  • Willing to participate in the study

Who cannot join

  • none

Trial locations and contacts

1 site in 1 country.

Thailand1 site
  • Faculty of Tropical Medicine

    Bangkok, Bangkok, 10400

Other trials in Thailand

About this study

RATIONALE:

Digital technology plays a key role in modern healthcare, impacting diagnosis, treatment, and health information management. Vaccination is a critical tool for disease prevention, reducing healthcare costs, and enhancing quality of life. Managing vaccine records accurately is essential due to varying vaccine schedules and dosage requirements. Traditionally, paper-based vaccine records have faced challenges like loss, illegibility, and incomplete information. Digital solutions offer a more reliable method for managing vaccination data efficiently. A vaccine mobile application is a digital tool designed to improve record immunization by using mobile technology. These apps offer features like reliable vaccine information, immunization record tracking, and reminders for vaccinations. They also facilitate communication between individuals, healthcare providers, and public health systems, aiming to boost vaccine uptake and reduce hesitancy. Examples include ReadyVax offer evidence-based vaccine information to healthcare providers and patients, ImmunizeCA for managing immunization records in Canada, and MomsTalkShots, deliver tailored educational content to increase vaccine uptake among specific populations, like pregnant women. Some apps, like HANDI, assist in public health data management, while application SafeVac and v-safe monitor post-vaccination safety. In Thailand, apps like StatelessVac and RamaCovid have supported immunization efforts and Coronavirus disease 2019 (COVID-19) vaccination. Thus, advancing mobile health technologies are valuable tools for improving healthcare delivery and enhancing immunization practices in the modern era.

Read more

OBJECTIVE: To evaluate the prototype digital vaccine platform "TM-VAX" user by Technology Acceptance Model (TAM)

METHODOLOGY:

This is a single-center, cross-sectional study conducted in the Hospital for Tropical Diseases, Mahidol University, Bangkok, Thailand, between February and May 2025. The study will recruit 200 participants, divided into two groups: 30 healthcare providers and 170 patients. Participants will be allowed to use the TM-VAX application for a one-week trial. Data will be collected through a single online questionnaire (Jotform), with the researcher distributing the questionnaire link via the LINE application (if applicable) or in-person at the end of study (day7). Data collection takes time around 10-15 minutes. The questionnaire consists of three main parts: demographic data, usage experience, and satisfaction. The sections on usage and satisfaction were developed based on previous literature and validated tools such as the mHealth App Usability Questionnaire (MAUQ) and the Usefulness, Satisfaction, and Ease of Use (USE) Questionnaire. The investigators adapted the usage and satisfaction sections from the MAUQ, including 20 questions organized into two parts. Part 1 comprises four categories: Ease of Use (6 items), System Information and Functionality (5 items), Communication (3 items), and Satisfaction (6 items), which addresses overall user satisfaction. Responses are scored on a 5-point Likert scale, with a high score (5 points) indicating very high usage or satisfaction, and the lowest score (1 point) indicating low usage or satisfaction. Part 2 includes open-ended questions to gather users' opinions about a problem and obstacles in using the application, as well as suggestions for improvement. Some participants will be randomly selected to in-depth interview (if participants are willing to do so).

Being tested
digital vaccine platform "TM VAX" application

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • digital vaccine platform "TM VAX" applicationOther

    Physicians and healthcare providers and Patients will use the TM-VAX system for at least one week. Investigators will distribute the online questionnaire via Jotform through the LINE application at day 7, which will take around 10-15 minutes to complete. If participants have any questions or encounter any issues with the questionnaire, the research team will provide assistance and answer questions via the LINE application or in-person

Study groups in NCT06843876
Study groupRoleWhat they receive
Subgroup: Healthcare Provider and PatientsExperimentalNot described
Receives: Other: digital vaccine platform "TM VAX" application

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. User satisfaction score with the digital vaccine platform "TM-VAX" as measured by the Technology Acceptance Model (TAM) Questionnaire

    Measured: 1 week

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Feb 2025
  2. Study start1 May 2025
  3. Primary completion30 Oct 2025
  4. Study completion30 Oct 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
202 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06843876
Sponsor's protocol ID
MUTM 2025-003-01
Status last verified
Oct 2026
First submitted
18 Feb 2025
Last updated
9 Oct 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing digital vaccine platform "TM VAX" application in people with Evaluate the Prototype Digital Vaccine Platform, run by Mahidol University at 1 site in Thailand.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

User satisfaction score with the digital vaccine platform "TM-VAX" as measured by the Technology Acceptance Model (TAM) Questionnaire (time frame: 1 week). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in